All case studies

Diagnostics

Helping Wellcome Leap - a world-leading philanthropic organisation - to prioritise investment in 12 new diagnostics aiming to cut stillbirth rates by half

What we did:

As part of Wellcome Leap’s $50m "In Utero" program, engaged with funders, grantees, and industry experts to identify the most promising innovations to cut stillbirth rates
Evaluated 12 technologies against criteria for success in the US, UK, Uganda, and India
Designed a new pathway to scale that addressed health system structural barriers
Delivered commercialization training to scientific teams

Impact:

In Utero received $100m in additional funding to reduce global stillbirths in line with our recommendations
Through this new partnership with the Gates Foundation, the initiative was renamed "Uzima" with a focus on advancing innovations in Sub-Saharan Africa

Source: Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates

More in Diagnostics

View all case studies

Defining the value proposition, mapping reimbursement pathways, and identifying relevant CPT codes for a top-10 diagnostics company's clinical algorithms
Read the case study: Defining the value proposition, mapping reimbursement pathways, and identifying relevant CPT codes for a top-10 diagnostics company's clinical algorithms
Prioritising the next generation of neurology diagnostics through rigorous assessment of biomarker candidates
Read more: Prioritising the next generation of neurology diagnostics through rigorous assessment of biomarker candidates

Accelerate the adoption of your health innovation.